Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight...
(Source: Gilead Sciences Inc) -- Full Results from Four Phase 3 ASTRAL Studies of Sofosbuvir/Velpatasvir to be Presented -- SAN FRANCISCO--(BUSINESS WIRE)--Nov. 14, 2015-- Gilead Sciences, Inc....
View ArticleU.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single...
(Source: Gilead Sciences Inc) – Label Expanded to Include Patients with Genotypes 4, 5 and 6 and Patients Co-Infected with HIV – – Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be...
View ArticleEnanta Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir,...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections...
View ArticleMerck to Release Findings from Integrated Analysis of Six Phase 2 and 3...
(Source: Merck & Co Inc) KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated...
View ArticleAbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir,...
NORTH CHICAGO, Ill., Nov. 14, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data from its ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK®...
View ArticleAbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir,...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 14, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data from its ongoing Phase 3b TOPAZ-II study...
View ArticleSpring Bank Pharmaceuticals Presents Positive Phase 1 Data on SB 9200 at the...
MILFORD, Mass., Nov. 16, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today...
View ArticleBills aimed at reining in drug costs could hurt access to meds
Kentucky is a state with many health challenges, leading the nation in many forms of cancer, hypertension, heart disease and diabetes. The Centers for Disease Control and Prevention recently reported a...
View ArticleThreat of Cirrhosis Estimated to Peak by 2021, no End in Sight for HCC...
SAN FRANCISCO, Nov. 16, 2015 /PRNewswire/ -- The numbers of patients with cirrhosis and hepatocellular carcinoma (HCC) are predicted to rise in the near future but by how much and from which causes is...
View ArticleThe Burden of Hepatitis C Now That it Can be Cured and the Cost of Curing...
SAN FRANCISCO, Nov. 16, 2015 /PRNewswire/ -- Jagpreet Chhatwal, PhD, presented two studies at the annual meeting of the American Association for the Study of Liver Diseases that addressed the burden of...
View ArticleJanssen Presents New Data Assessing OLYSIO® (Simeprevir) in Combination with...
BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV (Janssen) today announced the preliminary results from the Phase IIa OSIRIS trial, at the Liver Meeting®, the Annual Meeting of the...
View ArticleArrowhead Presents Data Showing Robust Sustained Anti-viral Effects with...
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presents data at the AASLD Liver Meeting 2015® in an oral presentation and a poster...
View ArticleMedicare Spending On Breakthrough Hep C Cure To Nearly Double
WASHINGTON (AP) — Medicare spending on breakthrough medications for hepatitis C will nearly double this year, passing $9 billion, according to new government figures. That's raising insurance costs for...
View ArticleLeading Liver Doctors: Hepatitis C Patients Must Be Treated
SAN FRANCISCO, Nov. 16, 2015 /PRNewswire/ -- The American Association for the Study of Liver Diseases (AASLD) issued the following statement during The Liver Meeting® being held this weekend in San...
View ArticleGilead’s Zydelig® Combined with Bendamustine and Rituximab Shows Superior...
(Source: Gilead Sciences Inc) -- Interim Analyses Results from Study 115 to be Presented as a Late-Breaking Abstract at the American Society of Hematology (ASH) Annual Meeting -- FOSTER CITY,...
View ArticleLarge Cure Rate for Patients with Hepatitis C May Have a Significant Impact...
SAN FRANCISCO, Nov. 16, 2015 /PRNewswire/ -- The direct acting antivirals that have been used to treat many patients with hepatitis C virus and cure almost all treated in the past two years has led to...
View ArticleEnanta Pharmaceuticals Announces Investigational Regimen Containing Enanta’s...
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections...
View ArticleArrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and...
(Source: Arrowhead Research Corporation) PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presented...
View ArticleConatus Pharmaceuticals Announces Poster Presentations at AASLD Annual...
(Source: Conatus Pharmaceuticals Inc) - Caspase Inhibition Suppresses Production of Biologically Active Microparticles in Murine Model of Alcoholic Liver Disease - - Emricasan Improves Survival and...
View ArticleConatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
- Caspase Inhibition Suppresses Production of Biologically Active Microparticles in Murine Model of Alcoholic Liver Disease - - Emricasan Improves Survival and Portal Hypertension in Murine Model of...
View Article